Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 1;24(6):552-559.
doi: 10.5551/jat.RV17004. Epub 2017 Apr 19.

Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation

Sadao Takahashi  1
Affiliations
Review

Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation

Sadao Takahashi. J Atheroscler Thromb. .

Abstract

Very low-density lipoprotein (VLDL) receptor is a member of the low-density lipoprotein (LDL) receptor family. It binds triglyceride rich lipoprotein (TGRL) but not LDL, because it recognizes apolipoprotein (apo)E only but not apoB. The VLDL receptor functions as a peripheral lipoprotein receptor in concert with lipoprotein lipase (LPL) in heart, muscle, adipose tissue and macrophages. In contrast to the LDL receptor, VLDL receptor binds apo E2/2 VLDL and apoE3/3 VLDL particles, and its expression is not down-regulated by intracellular lipoproteins. It has been reported that both LDL-cholesterol (LDL-C) and postprandial triglyceride (chyromicron and VLDL remnants) are risk factors for human atherosclerotic cardiovascular disease (ASCVD). True ligands such as lipoprotein particles of the VLDL receptor are chyromicron remnant (CMR) and VLDL remnant (postprandial hyperlipidemia). Although the oxidized LDL (oxLDL)-scavenger receptors pathway is considered to be the main mechanism for macrophage foam cell formation, it seems that the TGRL-LPL-VLDL receptor pathway is also involved. Since Lp(a) is one of the ligands for the VLDL receptor, the Lp(a)-VLDL receptor pathway is another potential alternative. The expression of VLDL receptor protein in mouse macrophages is modest compared to that in rabbit and human macrophages, both in vitro and in vivo. Therefore, we need to elucidate the mechanism of human ASCVD not by using the mouse model and scavenger receptors pathway but instead using the rabbit model and VLDL receptor pathway, respectively.

Keywords: Atherosclerosis; Lipoprotein lipase; Lp(a); Macrophage foam cell formation; VLDL receptor.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Structure of the VLDL receptor and the LDL receptory10). PCSK9 binds the EGF-A site of both LDL receptor and VLDL receptor.
Fig. 2
Fig. 2
Top: Non-fasting serum triglyceride (TG) in LDL-R KO and double KO mice (n = 6). Bottom: HPLC profile during 24 h fasting times in LDL-R KO and double KO mice.
Fig. 3.
Fig. 3.
Schematic diagram of the putative TGRL-LPL-VLDL receptor and Lp(a)-VLDL receptor pathways for macrophage foam cell formation. CM: chyromicron, CMR: chyromicron remnant, VLDL: very low-density lipoprotein, IDL: intermediate-density lipoprotein, LPL: lipoprotein lipase, ECs: endothelial cells, SMCs: smooth muscle cells
See this image and copyright information in PMC

References

    1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993; 362: 801-809 - PubMed
    1. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol, 1995; 15: 551-561 - PMC - PubMed
    1. Chistiakov DA, Bobryshev YV, Orekhov AN. Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol Med, 2016; 20: 17-28 - PMC - PubMed
    1. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, Silver JM, McKee M, Freeman MW. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest, 2005; 115: 2192-2201 - PMC - PubMed
    1. Manning-Tobin JJ, Moore KJ, Seimon TA, Bell SA, Sharuk M, Alvarez-Leite JI, de Winther MP, Tabas I, Freeman MW. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol, 2009; 29: 19-26 - PMC - PubMed

MeSH terms